Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Enzyme and Proton-Activated Prodrugs for a Selective Cancer Therapy

Author(s): L. F. Tietze and T. Feuerstein

Volume 9, Issue 26, 2003

Page: [2155 - 2175] Pages: 21

DOI: 10.2174/1381612033454072

Price: $65

Open Access Journals Promotions 2
Abstract

This review is a survey of two approaches for a selective anticancer therapy that are based on a specific cleavage of specially designed non-toxic prodrugs with the liberation of a cytotoxic compound either by antibody-enzyme conjugates targeted to tumor-associated antigens or by acid-catalyzed hydrolysis of the prodrugs due to the increased concentration of hydronium ions in malignant tissue under hyperglycemic conditions. Herein, the design, synthesis and the biological testing of prodrugs are described.

Keywords: adept, antitumor agents, cancer therapy, enzymes, glycosides, monoclonal antibodies, prodrugs


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy